HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis.

AbstractBACKGROUND:
Anti-tumor necrosis factor alpha (anti-TNF- alpha ) antibodies have been used for the treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and psoriasis arthritis. Such antibody therapies result in a severe interference with the patient's immune system. Increased rates of upper respiratory tract infection, reactivation of latent tuberculosis, and other systemic infectious diseases have been reported among patients receiving anti-TNF- alpha antibodies.
METHODS:
As a note of caution, we describe a 57-year-old woman who received therapy with anti-TNF- alpha antibodies for RA refractory to methotrexate. After almost 2 years of treatment, she developed a severe cytomegalovirus (CMV) retinitis of the right eye.
RESULTS:
Laboratory assays revealed an immune status with nearly total loss of the cellular immune response and partial reduction of the humoral immune response. Intravenous treatment with ganciclovir, followed by oral administration of valganciclovir, resulted in an ophthalmological remission. Cessation of immunosuppressive therapy led to partial immunological reconstitution in the patient. Six months after discontinuation of immunosuppressive therapy, CMV retinitis of the left eye occurred but was treated successfully with a second course of oral valganciclovir.
CONCLUSION:
In the light of this first reported case of a serious CMV infection following therapy with anti-TNF- alpha antibodies, CMV infection should be considered in symptomatic patients.
AuthorsGeorg Haerter, Burkhard J Manfras, Yvonne de Jong-Hesse, Heike Wilts, Thomas Mertens, Peter Kern, Michael Schmitt
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 39 Issue 9 Pg. e88-94 (Nov 01 2004) ISSN: 1537-6591 [Electronic] United States
PMID15494900 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antiviral Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Valganciclovir
  • Ganciclovir
Topics
  • Antibodies, Monoclonal (adverse effects, immunology)
  • Antiviral Agents (therapeutic use)
  • Arthritis, Rheumatoid (complications, drug therapy, immunology)
  • Cytomegalovirus Retinitis (chemically induced, complications, drug therapy, immunology)
  • Female
  • Ganciclovir (analogs & derivatives, therapeutic use)
  • Humans
  • Infliximab
  • Middle Aged
  • Tumor Necrosis Factor-alpha (immunology)
  • Valganciclovir

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: